|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
|
WO2003016496A2
(en)
|
2001-08-20 |
2003-02-27 |
The Scripps Research Institute |
Zinc finger binding domains for cnn
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
CA2568344C
(en)
|
2004-05-27 |
2016-01-19 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
NO2510096T3
(enExample)
|
2009-12-10 |
2015-03-21 |
|
|
|
EP3399026B1
(en)
|
2010-06-14 |
2024-06-26 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
|
PH12014500247A1
(en)
|
2011-07-29 |
2014-03-24 |
Univ Pennsylvania |
Switch costimulatory receptors
|
|
EP3594245A1
(en)
|
2012-02-13 |
2020-01-15 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
EP4541818A3
(en)
|
2012-05-25 |
2025-07-23 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
SI3300745T1
(sl)
|
2013-02-15 |
2020-01-31 |
The Regents Of The University Of California |
Himerni antigenski receptor in postopki njihove uporabe
|
|
US9932607B2
(en)
|
2013-11-15 |
2018-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Site-specific integration of transgenes into human cells
|
|
US10934346B2
(en)
|
2014-02-14 |
2021-03-02 |
Bellicum Pharmaceuticals, Inc. |
Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
|
|
CA3190002A1
(en)
|
2014-02-14 |
2015-08-20 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
|
SG11201606934SA
(en)
|
2014-03-04 |
2016-09-29 |
Fate Therapeutics Inc |
Improved reprogramming methods and cell culture platforms
|
|
US20170158749A1
(en)
*
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
CA2959168A1
(en)
|
2014-09-02 |
2016-03-10 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
|
|
US11161907B2
(en)
*
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP3271463A4
(en)
|
2015-03-18 |
2018-08-01 |
Baylor College of Medicine |
Her2/erbb2 chimeric antigen receptor
|
|
CA3001917A1
(en)
|
2015-10-16 |
2017-04-20 |
Fate Therapeutics, Inc. |
Platform for the induction & maintenance of ground state pluripotency
|
|
CN108779174B
(zh)
*
|
2015-11-04 |
2022-11-29 |
希望之城公司 |
靶向her2的嵌合抗原受体
|
|
WO2017078807A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
CA3007473A1
(en)
|
2015-12-14 |
2017-06-22 |
Bellicum Pharmaceuticals, Inc. |
Dual controls for therapeutic cell activation or elimination
|
|
EP3405568A4
(en)
|
2016-01-20 |
2019-12-04 |
Fate Therapeutics, Inc. |
COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
|
|
BR112020007228A2
(pt)
|
2017-10-11 |
2020-10-13 |
Fate Therapeutics, Inc. |
reprogramação celular usando sistema de expressão de vetor plasmídeo temporal e transitório
|
|
US11649294B2
(en)
*
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
EP3712178A4
(en)
|
2017-11-14 |
2021-08-11 |
Green Cross Lab Cell Corporation |
ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
|
|
BR112020010597A2
(pt)
|
2017-12-08 |
2020-10-27 |
Fate Therapeutics, Inc. |
imunoterapias com o uso de células efetoras derivadas de ipsc intensificadas
|
|
KR20250048610A
(ko)
|
2017-12-22 |
2025-04-09 |
페이트 세러퓨틱스, 인코포레이티드 |
향상된 면역 효과기 세포 및 이의 용도
|
|
SG10201801219VA
(en)
*
|
2018-02-13 |
2019-09-27 |
Agency Science Tech & Res |
Anti-HER2 Antibodies
|
|
WO2019191495A1
(en)
|
2018-03-29 |
2019-10-03 |
Fate Therapeutics, Inc. |
Engineered immune effector cells and use thereof
|
|
US20210308183A1
(en)
|
2018-07-17 |
2021-10-07 |
The Regents Of The University Of California |
Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells
|
|
US20210388389A1
(en)
|
2018-10-30 |
2021-12-16 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
|
CA3133419A1
(en)
|
2019-03-21 |
2020-09-24 |
Gamida Cell Ltd. |
Expansion and use of expanded nk cell fractions suitable for transplantation in combination therapy
|
|
JP7727549B2
(ja)
*
|
2019-03-22 |
2025-08-21 |
セルティス・セラピューティクス・ピーティーワイ・リミテッド |
抗ｈｅｒ２結合分子
|
|
CA3146967A1
(en)
|
2019-07-17 |
2021-01-21 |
Fate Therapeutics, Inc. |
Immune effector cell engineering and use thereof
|
|
JP2022548943A
(ja)
|
2019-09-25 |
2022-11-22 |
フェイト セラピューティクス，インコーポレイテッド |
複数標的化エフェクター細胞およびその使用
|
|
IL291924A
(en)
|
2019-10-07 |
2022-06-01 |
Fate Therapeutics Inc |
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
|
|
JP7664913B2
(ja)
|
2019-10-17 |
2025-04-18 |
フェイト セラピューティクス，インコーポレイテッド |
免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用
|
|
MX2022006725A
(es)
|
2019-12-06 |
2022-08-22 |
Fate Therapeutics Inc |
Mejora de célula inmunitaria efectora derivada de ipsc mediante el uso de compuestos pequeños.
|
|
JP7737996B2
(ja)
|
2020-01-23 |
2025-09-11 |
エクスマ バイオテック コーポレイション |
Ｈｅｒ２に対するキメラ抗原受容体およびその使用方法
|
|
CA3184449A1
(en)
|
2020-05-22 |
2021-11-25 |
GC Cell Corporation |
Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
US20230390337A1
(en)
|
2020-11-04 |
2023-12-07 |
Fate Therapeutics, Inc. |
Engineered ipsc and persistent immune effector cells
|
|
WO2022098925A1
(en)
|
2020-11-04 |
2022-05-12 |
Fate Therapeutics, Inc. |
Engineered ipsc and immune effector cells for heterogenous tumor control
|
|
CN112391414A
(zh)
|
2020-11-17 |
2021-02-23 |
中国医学科学院基础医学研究所 |
一种靶向her2的car-t表达载体及其构建和应用
|
|
TW202229359A
(zh)
|
2020-11-30 |
2022-08-01 |
日商小野藥品工業股份有限公司 |
Her2標靶藥物
|
|
JP7707304B2
(ja)
|
2022-04-08 |
2025-07-14 |
フェイト セラピューティクス，インコーポレイティド |
腫瘍標的化のためのキメラ抗原受容体
|